Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.

about

Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.

Item

http://www.wikidata.org/entity/Q38829177

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cisplatin resistance in cell m ...... address early therapy failure.

@en

type

Item

label

Cisplatin resistance in cell m ...... address early therapy failure.

@en

prefLabel

Cisplatin resistance in cell m ...... address early therapy failure.

@en

P1476

Cisplatin resistance in cell m ...... address early therapy failure

@en

P2093

Elisa Blanco-González

http://www.w3.org/2001/XMLSchema#string

L María Sierra

http://www.w3.org/2001/XMLSchema#string

Leticia Aguado

http://www.w3.org/2001/XMLSchema#string

Marta Espina

http://www.w3.org/2001/XMLSchema#string

Marta I Sierra

http://www.w3.org/2001/XMLSchema#string

María Montes-Bayón

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of a splicing mutation in group A xeroderma pigmentosum

Systems biology of cisplatin resistance: past, present and future

The comet assay for DNA damage and repair: principles, applications, and limitations

Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway

A role for polymerase eta in the cellular tolerance to cisplatin-induced damage.

Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.

Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein.

Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.

HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer.

Recognition of cisplatin adducts by cellular proteins.

P304

564-574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C7MT00014F

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P Martínez Camblor

M Corte-Rodríguez

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28425536

http://www.w3.org/2001/XMLSchema#string

P921

biomarker